ASLAN Pharmaceuticals Operating Income

ASLAN Pharmaceuticals (ASLN) currently reports a operating income of $-35M as of March 2024. That compares with $-54M in the prior-year period — up 35.4% year over year. Use the charts on this page to explore ASLAN Pharmaceuticals's operating income history and peer comparisons.

ASLAN Pharmaceuticals's operating income increased from $-54M to $-35M — a 35.4% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ASLAN Pharmaceuticals reported $-35M in operating income as of March 2024. That compares with $-54M in the prior-year period — up 35.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-35M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ASLAN Pharmaceuticals, and consider following ASLN for alerts when major investors trade the stock.

ASLAN Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-35M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASLN with unrelated industries.